Related Experiment Video
Updated: May 17, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Obesity pharmacotherapy: current perspectives and future directions.
1Department of Pharmacology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, 202002, India. drmonikamisra@gmail.com
Current Cardiology Reviews
|October 25, 2012
Summary
Novel antiobesity drugs are being developed to combat the global obesity epidemic. These new pharmaceutical agents target key mechanisms in body weight regulation, offering hope for more effective treatments.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Obesity is a major global health issue with limited effective treatments.
- Neuroendocrine regulation of body weight offers new molecular targets for drug development.
Purpose of the Study:
- To review the development of novel antiobesity drugs.
- To discuss new drug candidates and targets based on energy homeostasis.
Main Methods:
- Review of current scientific literature on obesity and drug development.
- Analysis of mechanistic insights into neuroendocrine regulation of body weight.
- Categorization of antiobesity drug mechanisms.
Main Results:
- Antiobesity drugs target energy intake, expenditure, lipid metabolism, fat stores, adipocyte differentiation, or mimic caloric restriction.
- Several novel drug candidates and targets are under investigation.
- Some candidates are progressing through clinical trials.
Conclusions:
- Advances in understanding energy homeostasis are driving the development of new antiobesity medications.
- Novel pharmaceutical agents targeting specific molecular pathways show promise for treating obesity.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...